Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer: Committee papers
Cited by National Institute for Health and Care Excellence on
The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.